DT07 Rec'd PCT/PTO 17 FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK ATTORNEY'S DOCKET NUMBER OFFICE (MOINFIED) X-15822 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/524798 **CONCERNING A FILING UNDER 35 U.S.C. 371** PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/US2003/023268 18 August 2003 (18.08.2003) 23 August 2002 (23.08.2002) TITLE OF INVENTION: BENZYL MORPHOLINE DERIVATIVES APPLICANT(S) FOR DO/EO/US: Barry Peter CLARK, Peter Thaddeus GALLAGHER, Helen Louise HAUGHTON Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 1. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). a has been transmitted by the International Bureau. b. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). 6. 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). a. b. have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. c. have not been made and will not be made. d. 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form. 11. A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 12. to 18. below concern document(s) or information included: s included.

12.	X	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
13.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31						
14. 15.		Assignment has been recorded at reel, frame						
	х	A FIRST preliminary amendment.						
_		A SECOND or SUBSEQUENT preliminary amendment.						
16.		A Sequence Listing, 1.821 Statement, and diskette.						
17.	x	A power of attorney with attachments.						

18. Other items or information:

Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US2003/023268, filed 18 August 2003, which claims the benefit, of GB 0219685.5, filed 23 August 2002, and US provisional application 60/415,327, filed 01 October 2002."

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/524798 INTERNATIONAL APPLICATION N PCT/US2003/023268					O. ATTORNEY'S DOCKET NUMBER X-15822				
19. X The following		9		CA	LCULATIONS	PTO USE ONLY			
Basic National S		\$ 300.00			LECLATIONS				
National Stage S	earch Fee =								
	xamination Fee = .TIONAL STAGE F								
Application Leng	gth Fee								
Total Length (excluding sequence	ce listings)								
<u>85</u>	$100 \div 50 \times 250 = $								
			1 000 00						
Surcharge of \$130.00		\$	1,000.00						
from the earliest claim CLAIMS	ed priority date (37 C NUMBER FILED	<u> </u>							
Total claims	11 -20=	NUMBER EXTRA 0	RATE X \$50.0 0	\$					
Independent claims	2 -3=	_1	X \$200.00	1 4					
MULTIPLE DEPEND			+ \$360.00	$\downarrow \Psi$	660.00				
	TOTA	1 42	.00. 0 0						
Reduction by 1/2 for f Statement must also be	iling by small entity,	\$	<i>i</i> ·						
Statement must also be	o med (Note 37 CTK	1.9, 1.27, 1.20).	SUBTOTAL =	\$	1,360.00				
Processing fee of \$130 from the earliest claim		\$	3 1						
	(2)	= \$	1,360.00						
Fee for recording the eaccompanied by an ap		\$							
+									
		= \$	1,360.00						
					Amount to be	\$			
				\vdash	refunded charged	\$			
a. A check in t	he amount of \$			[Ψ					
b. X Please charg	e my Deposit Accour	nt No. 05-0840 in the amo		cove	er the above fees.	A duplicate			
copy of this sheet is enclosed.									
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive									
(37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO:									
ELI LILLY AND COMPANY									
PATENT DIVISION P.O. BOX 6288	ļ.	\leq							
INDIANAPOLIS, INDIANA 46206-6288 Arvie J. ANDERSON					9500	###### 5			
					25885 PATENT TRADEMARK OFFICE				
DAT 									
REGISTRATIO									